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Background: A non-invasive, easy-to-access marker of accelerated 
cardiac ageing would provide novel insights into the mechanisms and 
aetiology of cardiovascular disease (CVD) as well as contribute to risk 
stratification of those who have not had a heart or circulatory event. 
Our hypothesis is that differences between an ECG-predicted and 
chronologic age of participants (δage) would reflect accelerated or 
decelerated cardiovascular ageing 
Methods: A convolutional neural network model trained on over 
700,000 ECGs from the Mayo Clinic in the U.S.A was used to predict 
the age of 4,542 participants in the Know Your Heart study conducted 
in two cities in Russia (2015-2018). Thereafter, δage was used in linear 
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regression models to assess associations with known CVD risk factors 
and markers of cardiac abnormalities. 
Results: The biomarker δage (mean: +5.32 years) was strongly and 
positively associated with established risk factors for CVD: blood 
pressure, body mass index (BMI), total cholesterol and smoking. 
Additionally, δage had strong independent positive associations with 
markers of structural cardiac abnormalities: N-terminal pro b-type 
natriuretic peptide (NT-proBNP), high sensitivity cardiac troponin T 
(hs-cTnT) and pulse wave velocity, a valid marker of vascular ageing. 
Conclusion: The difference between the ECG-age obtained from a 
convolutional neural network and chronologic age (δage) contains 
information about the level of exposure of an individual to established 
CVD risk factors and to markers of cardiac damage in a way that is 
consistent with it being a biomarker of accelerated cardiovascular 
(vascular) ageing. Further research is needed to explore whether 
these associations are seen in populations with different risks of CVD 
events, and to better understand the underlying mechanisms 
involved.
Keywords 
Cardiovascular disease, Biomarkers, Aging, Machine Learning, Russian 
Federation
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Introduction
The concept of biological age as distinct to chronologic age 
has attracted substantial interest. From a public health and 
clinical perspective, a valid and reliable measure of biological 
age would contribute to risk stratification and prioritisation 
of individuals or groups for treatments and interventions to 
reduce exposure to risk factors.
Various molecular biomarkers of biological age have been 
proposed including telomere length1 and DNA-methylation 
patterns2,3. These markers require invasive procedures, including 
blood taking and processing of DNA samples. Moreover, attempt-
ing to determine biological age of a particular organ as opposed 
to techniques which use leucocyte telomere lengths to derive 
a general biological age for example4 requires tissue-specific 
samples. These factors make them unsuitable for routine use in 
clinical practice, as well as making their collection and analy-
sis in large population-based studies prohibitively expensive. 
Establishing a new biomarker which is non-invasive and easily 
deployable at large scale in all settings, including resource 
constrained ones would therefore have many advantages.
The concept of heart age has been previously used to assess the 
physiologic ageing of the cardiovascular system5. A range of 
heart age prediction tools have been developed and typically 
require a combination of biochemical (e.g. serum cholesterol 
levels (LDL, HDL)), diabetes diagnosis, etc.) and other inputs 
(e.g. chronologic age, body mass index (BMI), diastolic and 
systolic blood pressure (DBP and SBP), mean arterial pressure 
(MAP))6. Others incorporate imaging parameters such as coro-
nary artery calcification, and carotid intima-media thickness 
into their risk prediction models5,7,8.
The electrocardiogram (ECG) is a ubiquitous and key clinical 
tool to carry out cardiovascular disease (CVD) risk stratifica-
tion, diagnosis and prognosis9,10. We have recently developed 
a deep-learning algorithm that has been applied to routinely 
collected digitised 12-lead ECGs from a large clinical popu-
lation in the U.S.A that has achieved high-accuracy in the 
prediction of left ventricular systolic dysfunction (LVSD) both 
retrospectively11 and prospectively12, and atrial fibrillation while 
in normal sinus rhythm13.
We have also developed a separate deep-learning model based 
on the same population to accurately predict biological age 
exclusively from digitised 12-lead ECG data14. Subtracting true 
chronologic from ECG-predicted age (ECG-age) yields a 
difference that we call δage (delta-age). This metric will be posi-
tive for individuals predicted to be biologically older than their 
chronologic age, or negative if predicted to be younger. In the 
US clinical population used to train the prediction algorithm, 
the predicted age had a mean absolute error of 7 years (SD: 
5.6 years) compared to chronologic age14. A δage of 7 years or 
greater predicted a higher risk of CVD events as well as a higher 
prevalence of low ejection fraction, hypertension and coronary 
disease14.
We suggest that δage may be regarded as a biologically proxi-
mal marker of the relative rate of cardiovascular ageing that 
reflect cumulative damage to date. We propose that it may 
have the potential for CVD risk stratification and case 
management as well as being a powerful tool for research to 
elucidate novel mechanisms of accelerated cardiac ageing and 
identify potential drivers of CVD differences across populations 
and between individuals.
In this study, we investigate how the novel biomarker 
ECG-derived δage relates to CVD risk profiles in a large cross- 
sectional study. We do this by studying the association of δage 
with established CVD risk factors as well as markers of age-
related cardiovascular abnormalities in a cross-sectional study 
conducted in adults (35–69 years) from two Russian cities 
(Arkhangelsk and Novosibirsk; 2015–18).
Methods
Data sources and population
We used data obtained in a cross-sectional study in the Russian 
cities of Arkhangelsk and Novosibirsk. The study population 
included 4,542 men and women aged 35–69 years recruited 
from the general population between 2015 and 2018, as 
described in detail elsewhere15. All participants provided written 
informed consent as detailed in a previous publication describ-
ing the study protocol15. Ethical approval for the study was 
received from the ethics committees of the London School 
of Hygiene & Tropical Medicine (approval number 8808 
received 24.02.2015; for substudy involving patients in treat-
ment for alcohol problems approval number 12018; received 
11/01/2017), Novosibirsk State Medical University (approval 
number 75 approval received 21/05/2015), the Institute 
of Preventative Medicine (no approval number; approval 
received 26/12/2014), Novosibirsk and the Northern State 
Medical University, Arkhangelsk (approval number 01/01-15 
received 27/01/2015; for substudy involving patients in treat-
ment for alcohol problems approval number 05/11-16 
received 02/11/2016).
Information on smoking status, alcohol use and education level 
were obtained through computer assisted personal interview 
(CAPI) questionnaires at baseline interview15. Alcohol use was 
assessed using the Alcohol Use Disorders Identification Test 
(AUDIT) instrument16. Education was coded as 3 categories 
(incomplete secondary, secondary and higher education) as used 
in an earlier Russian study17.
Participants were invited for a health check where a question-
naire and physical examination were performed in one of three 
study clinics15. Of those contacted and invited to take part, 47% 
attended the health check. A resting 10–25 seconds digital 
12-lead ECG was obtained using the Cardiax device (IMED 
Ltd, Hungary) and the raw ECG signal was stored digitally15. 
Blood pressure and pulse rate were measured using the OMRON 
705 IT automatic blood pressure monitor (OMRON Health-
care). The mean value of the second and third readings of 
systolic (SBP) and diastolic blood pressure (DBP) were used 
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where height (h; metres) was averaged across two measure-
ments and obtained following previously defined methods15 
and weight (w; kg) was obtained using the TANITA BC 418 
body composition analyser (TANITA, Europe GmbH) or a 
weighing scale when the TANITA could not be used15. Pulse 
wave velocity was obtained using the Vicorder device (Skidmore 
Medical Ltd, UK). Up to 8 pulse wave measurements were 
obtained based on quality of the measurements15, and the pulse 
wave velocity measurement used in this study was the average of 
all available measurements.
During the course of the health check, blood was obtained from 
the participants who were requested not to eat or drink alcohol 
during the 4 hours immediately before their booked appoint-
ment. Serum samples were taken, centrifuged, and aliquoted 
into 1.8‐mL barcoded cryovials which were then frozen at 
−80°C within 2 hours. These were then analysed in a sin-
gle batch at the end of the fieldwork at an independent labora-
tory in Moscow. The lipid profile of each sample was measured 
and included high-density and low-density lipoproteins.
High‐sensitivity cardiac troponin T (hs‐cTnT) and N‐terminal 
pro‐B‐type natriuretic peptide (NT‐proBNP) were measured 
using a high‐sensitivity electrochemiluminescence immunoassay 
(Roche Diagnostics GmbH, Hitachi, Japan) on a Cobas e411 
analyser. The lower limit of detection for hs‐cTnT test was 
3 ng/L. Of the total 3,864 participants, 69 (1.79%) were below 
the limit of detection for Hs-cTnT which was 3 ng/L and were 
recoded to 2.9 ng/L18. Similarly, 22 participants (0.57%) were 
below the lower limit of detection for NT‐proBNP which was 
5 ng/L and their values were recoded to 4.9 ng/L18.
Presence of plaques was estimated by high-resolution ultrasound 
using the Vivid q machine (GE HealthCare) with 6~13 MHz 
linear transducer in both side carotid arteries (common carotid 
artery, bifurcation, internal carotid artery). The still image 
for each identified plaque and cine loops in transverse and 
sagittal views was recorded digitally. The off-line reading 
of recorded images was performed with EchoPAC software 
(GE Vingmed Ultrasound, Horten, Norway) by an experienced 
reader (AR). Carotid plaque was defined as a focal structure 
encroaching into the arterial lumen at least 0.5 mm or 50% of 
the surrounding intima media thickness (IMT) value or IMT 
>1.5 mm as measured from the media-adventitia interface to 
the intima-lumen interface based on Mannheim Consensus19. 
Detailed methods are previously described elsewhere19,20. The 
current analysis uses the presence or absence of any plaques – a 
dichotomous variable.
ECG analysis of patients with multiple ECGs
During the course of the data collection, 402 randomly selected 
participants (202 in Arkhangelsk and 200 in Novosibirsk) were 
invited to retake the complete assessments performed in the 
study, including both baseline questionnaire and health-check 
measurements. The repeat interviews and examinations were 
performed one year after the first interview, with a two-week 
either side date difference allowed21. Out of the 402 total 
records, 369 repeat ECGs were available and were linked 
to the original ones taken a year earlier, both δage and a 
between-pair Pearson’s correlation was calculated using R 
v3.4.4 base functions.
Overview of the AI model
A convolutional neural network (CNN) model using Keras with 
a Tensorflow 2 (Google, Mountain View, CA) backend was 
previously developed and validated. A total of 774,783 unique 
subjects with ECGs were used to develop the neural network: 
399,750 in the training set, 99,977 in the internal validation 
set and 275,056 ECGs in the holdout testing set. The network 
contained stacked blocks of convolutional, max pooling, and 
batch normalization22. A detailed description of the network is 
described in our previously published paper14. The network 
had a single output (ECG-age) as continuous number. This 
model was not re-trained using the Russian data. The measure 
δage was obtained by subtracting the chronologic age from the 
ECG-age. In this way, a positive δage would represent an indi-
vidual in which the ECG would predict an older age than 
the chronologic age (older by ECG), while a subject with 
a negative δage would represent an individual found to be 
younger by ECG.
Statistical methods
R v3.4.4. statistical software was used for statistical analysis. 
Continuous variables were standardised as SD units by sub-
tracting the average and dividing by the standard deviation to 
allow comparable effects in regression analyses. Hs-cTnT and 
NTroBNP measurements were natural log transformed as they 
were not Gaussian distributed.
We used linear regression models to assess association of 
the risk factors as exposures using δage as the outcome. All 
models were adjusted for a priori confounders including chrono-
logic age, sex and clinic where the measurement was taken, 
where the latter accounted for any systematic potential protocol 
and device calibration differences. Real chronologic age was 
also included in every model to remove the effects of any poten-
tial correlation between δage and chronologic age. A test for 
trend for smoking was performed by converting the ordered 
categories of number of cigarettes smoked into integer values. 
Basic models including one risk factor at a time were further 
adjusted for other risk factors plus education level.
We assessed whether any of the main effects varied by sex by 
undertaking an analysis of interactions. To assess the extent 
to which any results might be driven by the subset of people 
with pre-existing cardiovascular disease, sensitivity analysis 
was carried out by excluding any participant with either an 
ECG indicated myocardial infarction (MI) or self-reported 
history of stroke or MI and repeated the same linear regression 
models.
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Results
A total of 4,780 resting ECGs of 15 seconds were collected 
from 4,378 participants in the main study sample (MSS) (402 
ECGs were repeated for a randomly selected subset of MSS 
participants one year later in the repeat study sample (RSS)). 
After exclusion of participants with missing data for any vari-
able considered, the final set consisted of 3,863 and 369 ECGs 
for the MSS and RSS, respectively. Overall, mean chrono-
logic age was 54.6 years (SD 9.7) on the day of the first ECG 
measurement and 1,597 (41.3%) of them were men.
The ECG-age for all participants had a mean of 59.8 years 
(SD 10.6). The average δage of this study population was 
5.32 years (SD 7.6) (Figure 1). This difference in predicted 
versus chronologic age was observed to be relatively constant for 
the age groups between 35 and 60 years old, with average δage 
converging towards the line of identity at older ages (Figure 2). 
The RSS measurements were correlated with their respective 
MSS measurements from the previous year (Pearson correlation 
r = 0.72) (Figure 3).
Linear regression analysis of known CVD risk factors on δage 
(adjusted for sex, chronologic age and clinic where the ECG 
was taken) showed that SBP, DBP, MAP, BMI, LDL/HDL 
ratio and smoking status were associated with an increase in 
δage (P<0.0001); DBP and BMI showed the strongest effects, 
which were almost identical (1 SD unit increase leading to + 
~1.6 δage years) (Table 1). These effects were attenuated on 
mutual adjustment for confounders, but all variables remained 
statistically significant other than the AUDIT alcohol score 
(Table 2). Mutually adjusting smoking status and BMI revealed 
an increase in the effect of smoking. Further adjustment 
for education had minimal effect (results not shown).
In the fully adjusted model (Table 2), chronological age showed 
a negative association with δage, with a 2.66 (95% CI: 2.40, 
2.92) years reduction in δage for a 10-year increase in chrono-
logic age, and this effect was driven by the older age groups 
(Figure 2). This is consistent with the line of best fit moving 
closer to the line of identity with increasing chronological age 
as shown in Figure 2. δage differed between the two cities, in 
particular, the Novosibirsk population had a lower δage than 
that in Arkhangelsk (-1.21, 95% CI: -1.47, -0.54 years). Sex 
showed no significant effect on δage when studied by itself or 
in relation to individual CVD risk factors and no significant 
sex-interactions were observed. In the fully adjusted model 
(Table 2) female participants had higher δage years (0.68, 95% 
CI: 0.12, 1.24) compared to males.
Two markers of cardiac pathology (NTproBNP and hs-cTnT) 
showed positive associations between their log concentrations 
Figure 1. Histogram of δage (years) in Russian adults (n=3,864, 35–69 years) from two cities in Russia.
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Figure 2. Scatterplot of ECG predicted age against chronologic age in Russian adults (n=3,864, 35–69 years) from 2 cities in 
Russia.
Figure 3. Scatterplot of δage for 369 records of the Main Study Subset participants (MSS, Year 1) against δage for linked Repeat 
Study Subset participants (RSS, Year 2), Pearson correlation (r) = 0.72.
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Table 1. Associations of cardiovascular disease risk factors with δage (n = 3,863) 
adjusted for age, sex and clinic.
Exposures * δage (years) (95% CI) p-value
Mean systolic blood pressure (SD units) 1.30 [1.05, 1.55] <0.0001
Mean diastolic blood pressure (SD units) 1.62 [1.39, 1.86] <0.0001
Mean arterial pressure (SD units) 1.56 [1.32, 1.80] <0.0001
Mean pulse rate (SD units) -0.12 [-0.25, 0.11] 0.30
Body mass index (SD units) 1.61 [1.38, 1.84] <0.0001
Ratio LDL/HDL (SD units) 0.84 [0.6, 1.07] <0.0001
AUDIT score (score units [0–40]) 0.06 [-0.01, 0.13] 0.11
Smoking status
Never smoked [reference] 0 - -
Ex-smoker/Non-regular smoker 0.50 [-0.09, 1.09] 0.10
Regular smoker (<=20 cigarettes) 0.67 [0.02, 1.31] 0.042
Heavy smoker (>20 cigarettes) 1.56 [0.19, 2.92] 0.026
P-value for trend 0.0032
(*) Systolic Blood Pressure, Diastolic Blood Pressure, Mean Arterial Pressure, Mean Pulse Rate, Body Mass 
Index, and the ratio of Low-Density Lipoproteins over High-Density Lipoproteins (Ratio LDL/HDL) were 
transformed into SD units by subtracting the mean and dividing by the standard deviation so that their effects 
were comparable. Alcohol Use Disorders Identification Test (AUDIT).
Table 2. Mutually adjusted associations of established cardiovascular disease risk 
factors with δage (n = 3,863) additionally adjusted for age, sex and clinic.
Exposures * δage (years) (95% CI) p-value
Mean systolic blood pressure (SD units) 1.01 [0.76, 1.26] <0.0001
Body mass index (SD units) 1.34 [1.09, 1.58] <0.0001
Ratio LDL/HDL (SD units) 0.35 [0.10, 0.59] 0.0052
AUDIT score (score units [0–40]) 0.01 [-0.07, 0.08] 0.77
Smoking status Never smoked [reference] 0 - -
Ex-smoker/Non-regular smoker 0.40 [-0.18, 0.98] 0.17
Regular smoker (<=20 cigarettes) 0.79 [0.15, 1.42] 0.015
Heavy smoker (>20 cigarettes) 1.22 [-0.12, 2.56] 0.074
P-value for trend 0.0058
(*) Systolic Blood Pressure, Body Mass Index, and the ratio of Low-Density Lipoproteins over High-Density 
Lipoproteins (Ratio LDL/HDL) were transformed into SD units by subtracting the mean and dividing by the 
standard deviation so that their effects were comparable. Alcohol Use Disorders Identification Test (AUDIT).
and δage (P<0.0001) (Table 3). Adjustment for other CVD 
risk factors marginally increased the strength of associa-
tion of NTproBNP and attenuated the association of hs-cTnT 
with age. The associations of both of these biomarkers with 
δage remained significant after adjustment for risk factors 
(Table 3). These associations were marginally reduced by 
adjustment for education level.
Carotid plaque was associated with δage after adjustment for 
age, sex and clinic but this association was attenuated to null 
after further adjustment for CVD risk factors. Pulse wave 
velocity was positively associated with δage, although adjust-
ment for CVD risk factors attenuated the effect appreciably 
(Table 3); this was largely accounted for by a shared association 
with systolic blood pressure.
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Finally, we estimated the independent associations of MAP 
and pulse wave velocity on δage (Table 4). This highlighted the 
strong significant association of MAP and pulse wave veloc-
ity with δage with MAP showing an effect of 1.57 (95% CI: 
1.33, 1.81) δage years increase per standard deviation unit 
increase of MAP (Table 4, Model 1). On mutual adjustment, 
the association between pulse wave velocity and δage was sub-
stantially reduced, while the association between MAP and 
δage only marginally reduced. Additional adjustment for 
other CVD risk factors further attenuated these associations. 
However, the association with MAP remained statistically 
significant (P<0.0001).
Sensitivity analyses were performed to further explore the robust-
ness of the effects observed. Following exclusion of all par-
ticipants who self-reported having had a myocardial infarction 
or stroke or were found to have ECG-based evidence of myo-
cardial infarction, associations with CVD risk factors changed 
only slightly. There was an increase of the adjusted associa-
tion with smoking and the LDL/HDL ratio and a reduction 
Table 3. Associations of markers of heart abnormalities and ageing biomarkers with 
δage adjusted for various factors (n = 3,843).
Model 1: Adjusted for Age, 
Sex and Clinic
Model 2: Model 1 + 
Significant Risk Factors from 
Table 2 (BMI, SBP, Ratio LDL/
HDL and Smoking status)
Exposures *
δage 
(years) (95% CI) p-value
δage 
(years) (95% CI) p-value
Log Troponin T (SD 
units) 0.52 [0.26, 0.79] <0.0001 0.28 [0.02, 0.54] 0.032
Log NTproBNP (SD units) 0.82 [0.57, 1.08] <0.0001 0.88 [0.63, 1.14] <0.0001
Presence of carotid 
plaque (yes/no) 0.70 [0.16, 1.24] 0.012 0.19 [-0.35, 0.72] 0.50
Mean pulse wave 
velocity (SD units) 0.81 [0.54, 1.08] <0.0001 0.27 [-0.02, 0.55] 0.065
Mean pulse wave 
velocity (SD units) ** 0.81 [0.54, 1.08] <0.0001 0.38 [0.10, 0.67] 0.007
(*) Log Troponin T, Log NTproBNP and mean pulse wave velocity were transformed into SD units by 
subtracting the mean and dividing by the standard deviation so that their effects were comparable.
(**) Not adjusted by Systolic Blood Pressure (SBP).
Ratio of Low-Density Lipoproteins over High-Density Lipoproteins (Ratio LDL/HDL); Body Mass Index (BMI).
Table 4. Associations of mean arterial pressure and pulse wave velocity on δage adjusted for various factors (n = 3,843).
Model 1: Adjusted for Age, 
Sex and Clinic
Model 2: Model 1 + Mutual 
Adjustment
Model 3: Model 2 + Adjustment 




(years) (95% CI) p-value
δage 
(years) (95% CI) p-value δage (years) (95% CI) p-value
Mean arterial 
pressure (SD 
units) 1.57 [1.33, 1.81] < 0.0001 1.49 [1.23, 1.75] <0.0001 1.34 [0.93, 1.45] <0.0001
Mean pulse wave 
velocity (SD units) 0.81 [0.54, 1.08] < 0.0001 0.26 [-0.02, 0.54] 0.072 0.20 [-0.08, 0.47] 0.17
(*) Mean arterial pressure and mean pulse wave velocity were transformed into SD units by subtracting the mean and dividing by the standard 
deviation so that their effects were comparable. Ratio of Low-Density Lipoproteins over High-Density Lipoproteins (Ratio LDL/HDL); Body Mass 
Index (BMI).
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Table 5. Sensitivity analysis of the associations of cardiovascular disease risk factors with 
δage (n = 3,536) adjusted for age, sex and clinic. Participants were excluded if they presented with 
either self-reported myocardial infarction, self-reported stroke or ECG-based evidence of myocardial 
infarction.
Exposures * δage (years) (95% CI) p-value
Mean systolic blood pressure (SD units) 1.28 [1.02, 1.54] <0.0001
Mean diastolic blood pressure (SD units) 1.66 [1.42, 1.91] <0.0001
Mean arterial pressure (SD units) 1.57 [1.32, 1.83] <0.0001
Mean pulse rate (SD units) -0.16 [-0.40, 0.08] 0.19
Body mass index (SD units) 1.61 [1.37, 1.86] <0.0001
Ratio LDL/HDL (SD units) 0.89 [0.64, 1.14] <0.0001
AUDIT score (score units [0-40]) 0.07 [0.00, 0.15] 0.065
Smoking status
Never smoked [reference] 0 - -
Ex-smoker/ Non-regular smoker 0.50 [-0.12, 1.12] 0.12
Regular smoker (<=20 cigarettes) 0.72 [0.04, 1.40] 0.037
Heavy smoker (>20 cigarettes) 1.94 [0.53, 3.35] 0.0071
P-value for trend 0.0029
(*) Systolic Blood Pressure, Diastolic Blood Pressure, Mean Arterial Pressure, Mean Pulse Rate, Body Mass Index and 
the ratio of Low-Density Lipoproteins over High-Density Lipoproteins (Ratio LDL/HDL) were transformed into SD units 
by subtracting the mean and dividing by the standard deviation so that their effects were comparable. Alcohol Use 
Disorders Identification Test (AUDIT).
in the strength of association with hs-cTnT and NT-proBNP 
(Table 5–Table 7).
Discussion
In this study we have shown that the difference between the 
ECG-age obtained from a convolutional neural network and 
chronologic age, called here delta-age (δage), contains informa-
tion about the level of exposure of an individual to established 
CVD risk factors and to markers of cardiac damage.
This novel biomarker is strongly associated in this Russian 
study population with established risk factors of CVD (systolic 
blood pressure, body mass index, smoking and serum choles-
terol levels) in a direction that is intuitively consistent with 
δage being a marker of accelerated cardiovascular (vascular) 
ageing. In parallel we have found strong evidence that δage is 
associated with established markers of cardiac damage such as 
NTproBNP and hs-cTnT.
In order to explore the potential of this marker as a measure 
of accelerated cardiovascular ageing, we studied its associa-
tion with pulse wave velocity, an established marker of vascular 
ageing. Carotid femoral pulse wave velocity is a proxy meas-
urement for aortic stiffness23. Pulse wave velocity is known 
to be pressure dependent24, which could account for the 
strong attenuation of the effect of the association of pulse 
wave velocity with δage we observe when arterial pressure is 
accounted for. Despite this, intrinsic stiffness independent of the 
measured arterial pressure is a marker of ageing25. In this study, 
we have assessed this cumulative damage by considering both 
MAP and pulse wave velocity in the same model, this showed 
a positive association of pulse wave velocity with δage even 
after adjustment for MAP. Due to the complex nature of the 
interaction between pulse wave velocity and blood pres-
sure, further research with well-powered cohorts would be 
required to disentangle the relationship of δage with traditional 
vascular markers of ageing.
The robustness of the δage biomarker and its ability to cap-
ture information about the intrinsic cardiovascular health of 
an individual can be observed in the reproducibility of our 
measurements taken one year apart in this study (Pearson’s 
r=0.72), and across several years in a previous study14. Both 
of these results suggest that this measure is stable across time. 
In addition, δage captured the effect of complex interactions 
such as the negative confounding effect of smoking on BMI and 
the positive trend on δage observed with increasing amounts 
of cigarettes smoked. Of special interest would be to assess 
the effects on δage in an intervention study aimed at CVD 
health and risk improvement.
One of the most striking results from our study is to show 
how an algorithm that has been exclusively trained in a clini-
cal population from the U.S.A provides such an informative 
picture about the CVD risk of a different population in Russia, 
suggesting that the information captured by the algorithm is 
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Table 7. Sensitivity analysis on the effect of markers of heart abnormalities and 
ageing biomarkers on δage (n = 3,521). Participants were excluded if they presented with 
either self-reported myocardial infarction, self-reported stroke or ECG-based evidence of 
myocardial infarction.
Model 1: Adjusted for Age, 
Sex and Clinic
Model 2: Model 1 + 
Significant Risk Factors from 
Table 1 (BMI, SBP, Ratio LDL/
HDL and Smoking status)
Exposures * δage 
(years)
(95% CI) p-value δage 
(years)
(95% CI) p-value
Log Troponin T (SD 
units)
0.41 [0.13, 0.68] 0.0036 0.17 [-0.10, 0.44] 0.21
Log NTproBNP (SD units) 0.69 [0.42, 0.96] <0.0001 0.76 [0.49, 1.03] <0.0001
Presence of carotid 
plaque (yes/no)
0.59 [0.03, 1.15] 0.038 0.05 [-0.51, 0.60] 0.86
Mean pulse wave 
velocity (SD units)
0.82 [0.54, 1.11] <0.0001 0.28 [-0.01, 0.58] 0.060
Mean pulse wave 
velocity (SD units) **
0.82 [0.54, 1.11] <0.0001 0.60 [0.32, 0.88] <0.0001
(*) Log Troponin T, Log NTproBNP and mean pulse wave velocity were transformed into SD units by 
subtracting the mean and dividing by the standard deviation so that their effects were comparable.
(**) Not adjusted for Systolic Blood Pressure (SBP).
Ratio of Low-Density Lipoproteins over High-Density Lipoproteins (Ratio LDL/HDL); Body Mass Index (BMI).
Table 6. Sensitivity analysis of the Mutually adjusted associations of established cardiovascular 
disease risk factors with δage (n = 3,563) additionally adjusted for age, sex and clinic. 
Participants were excluded if they presented with either self-reported myocardial infarction, self-reported 
stroke or ECG-based evidence of myocardial infarction.
Exposures * δage (years) (95% CI) p-value
Mean systolic blood pressure (SD units) 0.98 [0.72, 1.24] <0.0001
Body mass index (SD units) 1.32 [1.06, 1.58] <0.0001
Ratio LDL/HDL (SD units) 0.41 [0.16, 0.67] 0.0016
AUDIT score (score units [0–40]) 0.01 [-0.06, 0.09] 0.70
Smoking status
Never smoked [reference] 0 - -
Ex-smoker/ Non-regular smoker 0.40 [-0.21, 1.00] 0.19
Regular smoker (<=20 cigarettes) 0.78 [0.11, 1.45] 0.021
Heavy smoker (>20 cigarettes) 1.57 [0.19, 2.96] 0.026
P-value for trend 0.0043
(*) Systolic Blood Pressure, Diastolic Blood Pressure, Mean Arterial Pressure, Mean Pulse Rate, Body Mass Index and 
the ratio of Low-Density Lipoproteins over High-Density Lipoproteins (Ratio LDL/HDL) were transformed into SD units 
by subtracting the mean and dividing by the standard deviation so that their effects were comparable. Alcohol Use 
Disorders Identification Test (AUDIT).
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likely to be a generalizable marker of accelerated or decelerated 
cardiovascular ageing of an individual, and therefore robust and 
applicable across a number of healthcare settings.
In the context of this Russian study, it is striking to observe 
that the mean δage (5.32 years in the overall study) is con-
sistently higher across all younger adults (ranging from 35 to 
60 years) and the strength of the association with both risk fac-
tors and markers of cardiac abnormalities described in this 
study increases when including only these younger adults in 
the models (data not shown). Previous studies showed that 
reduced telomere length, a biomarker of ageing, is associ-
ated with an increase in risk of CVD and all-cause mortality in 
an adult Russian cohort4. Furthermore, the difference between 
the ECG-predicted age from this model and chronologic age 
(δage) has been shown to be a strong independent predictor of 
cardiovascular and all-cause mortality in complementary work 
done in a separate population26. Combining these results with 
the presented data on CVD risk factors and markers of cardiac 
damage one could hypothesise that this novel biomarker con-
tains information which might help us understand the causes 
of the abnormally high CVD mortality in working-age adults 
in Russia and its relationship to the observed average δage, 
although similar mortality studies would need to be performed 
in Russia to confirm this.
A weakness of this study is that it was based on a population 
sample with suboptimal response rates. However, we are prima-
rily focussed on understanding associations within the studied 
population rather than wanting to generalise to the target popu-
lation of all residents of the two cities being studied. To this 
extent the potential lack of representativeness may not be 
that important. Other potential weaknesses include the fact 
that the devices and protocols used to measure ECGs were 
not the same in training and test samples (model design in the 
U.S.A and CVD risk analysis in Russia); however, despite that 
this non-random misclassification can add noise to our analy-
sis, the results obtained from the CVD risk factors analysis sug-
gest these measurements are robust with regards to expected 
direction of the associations. Finally, a strength of this study is 
the availability of a wide range of different CVD risk factors 
and markers of cardiovascular abnormalities.
Obtaining this novel proximal cardiovascular biomarker does 
not involve an added cost beyond performing a 12-lead ECG 
and therefore has the potential to be widely used in routine 
clinical settings, including in low- and middle-income countries 
and can be applied retrospectively to digitally-acquired or digi-
tized ECGs. Currently, there are hand-held devices which can 
undertake clinically approved ECGs in order to diagnose car-
diovascular phenotypes or illnesses such as atrial fibrillation and 
others. The use of these devices might open the door to even 
less costly real-time longitudinal assessments of cardiovascular 
health using deep-learning models27.
Further research is needed to explore whether the δage biomar-
ker has similar patterns of associations in other populations 
with different CVD contexts, as well as further explore and dis-
entangle the determinants of the δage gap using established 
ECG features known to be affected by ageing and other CVD 
risk factors. Other research avenues might explore the genetic 
and epigenetic determinants of δage. For implementation in a 
clinical setting, it will be important to identify clinically rel-
evant thresholds of this biomarker in order to establish CVD 
risk and streamline case management and prioritisation of 
patients.
Data availability
Data cannot be made available due to access needing to be 
reviewed by a steering committee upon request. All data used in 
this study can be requested through the Know Your Heart meta-
data portal (https://metadata.knowyourheart.science/) upon reg-
istration. Registered users are able to browse the variable-level 
metadata for the Know Your Heart study; however, the site does 
not provide access to the data themselves.
Bona fide researchers may apply to the study steering group 
(email: david.leon@lshtm.ac.uk) for an anonymised subset of 
the data. The primary criteria used by the steering group are 
scientific coherence of the proposed use of the data and the 
match between the stated aims of the proposed research and the 
variables requested. This means that applicants need to jus-
tify the sets of variables they wish to have. In some instances, 
the research topic of the application may be close to or 
replicates ongoing research either within the core team or 
by previous applicants. In these cases, this overlap would be 
communicated to the applicants with a suggestion for the way 
forward. More information can be found in the ‘User Guide’ 
document on the website.
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